Mira Pharmaceuticals reports preclinical pain relief data and updates on SKNY merger

Published 02/07/2025, 21:26
Mira Pharmaceuticals reports preclinical pain relief data and updates on SKNY merger

Mira Pharmaceuticals , Inc. (NASDAQ:MIRA), a $20.47 million market cap biotech company currently trading at $1.24, announced Wednesday that its proprietary drug candidate Mira-55, a non-psychoactive marijuana analog, demonstrated pain relief comparable to morphine in a validated animal model of inflammatory pain. According to InvestingPro data, the company has delivered an impressive 100% return over the past year, reflecting investor optimism in its development pipeline. According to the company’s statement in a Securities and Exchange Commission (SEC) filing, Mira-55 achieved these results without causing local inflammation or sedative effects.

Mira-55 is a synthetic analog designed to selectively activate CB2 receptors, which are linked to anti-inflammatory and analgesic responses, while exhibiting minimal activity at CB1 receptors associated with psychoactive effects. In a formalin-based rodent model, the candidate reduced pain sensitivity and restored pain thresholds to near-baseline levels, matching the efficacy of morphine, the opioid control in the study.

The company also stated that the U.S. Drug Enforcement Administration (DEA) has confirmed Mira-55 is not classified as a controlled substance, which removes a regulatory barrier for clinical development.

Mira Pharmaceuticals reported that Mira-55 complements its clinical-stage program Ketamir-2, an NMDA receptor antagonist currently in Phase 1 development for neuropathic pain. While the company is not yet profitable, InvestingPro analysis shows a strong current ratio of 12.86, indicating ample liquidity to fund its development programs.

Additionally, Mira Pharmaceuticals provided an update on its planned acquisition of SKNY Pharmaceuticals. The SEC has completed its review of the merger proxy without comment, allowing the company to proceed with shareholder approval and final steps toward closing the transaction. SKNY Pharmaceuticals is developing SKNY-1, an investigational therapy targeting obesity and nicotine addiction. Recent studies cited by the company indicate SKNY-1 achieved a 30% reduction in body weight without muscle loss and reversed nicotine cravings in preclinical models.

Mira Pharmaceuticals said it is advancing Mira-55 toward an Investigational New Drug (IND) submission to support future clinical trials for inflammatory pain indications. InvestingPro subscribers have access to additional financial health metrics and 7 more exclusive ProTips that could help evaluate the company’s development potential and investment outlook.

All information is based on a statement from Mira Pharmaceuticals in a recent SEC filing.

In other recent news, MIRA Pharmaceuticals, Inc. has announced significant developments regarding its drug candidate SKNY-1, which it plans to acquire from SKNY Pharmaceuticals, Inc. The drug demonstrated up to 30% weight loss and reduced cravings in an animal model, supporting its advancement toward further studies. MIRA is also progressing with its acquisition of SKNY Pharmaceuticals, a move approved by its Board of Directors, which could create a combined entity valued at over $60 million. Additionally, MIRA’s lead drug candidate, Ketamir-2, has been accepted for publication in the journal Frontiers in Pharmacology and is currently in Phase 1 clinical trials for neuropathic pain. The company plans to start a Phase 2a clinical trial by the end of 2025. MIRA Pharmaceuticals has also appointed Alan Weichselbaum as the new Chief Financial Officer, replacing Michelle Yanez. The company is preparing to participate in the BIO International Convention 2025 to explore potential strategic collaborations. These developments reflect MIRA’s ongoing efforts to expand its therapeutic offerings and strengthen its executive team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.